Cancer Biology Program, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA, United States.
Department of Microbiology and Immunology, The University of Iowa, Iowa City, IA, United States.
Front Immunol. 2022 Aug 22;13:989000. doi: 10.3389/fimmu.2022.989000. eCollection 2022.
Pharmacological ascorbate (i.e., intravenous infusions of vitamin C reaching ~ 20 mM in plasma) is under active investigation as an adjuvant to standard of care anti-cancer treatments due to its dual redox roles as an antioxidant in normal tissues and as a prooxidant in malignant tissues. Immune checkpoint inhibitors (ICIs) are highly promising therapies for many cancer patients but face several challenges including low response rates, primary or acquired resistance, and toxicity. Ascorbate modulates both innate and adaptive immune functions and plays a key role in maintaining the balance between pro and anti-inflammatory states. Furthermore, the success of pharmacological ascorbate as a radiosensitizer and a chemosensitizer in pre-clinical studies and early phase clinical trials suggests that it may also enhance the efficacy and expand the benefits of ICIs.
药理剂量的抗坏血酸（即静脉输注维生素 C 使血浆中浓度达到约 20mM）因其在正常组织中作为抗氧化剂和在恶性组织中作为促氧化剂的双重氧化还原作用，正在作为标准治疗癌症的辅助药物而受到广泛研究。免疫检查点抑制剂（ICIs）是许多癌症患者极具前景的治疗方法，但面临着包括反应率低、原发性或获得性耐药以及毒性等多种挑战。抗坏血酸可调节先天和适应性免疫功能，在维持促炎和抗炎状态之间的平衡方面发挥着关键作用。此外，药理剂量抗坏血酸在临床前研究和早期临床试验中作为放射增敏剂和化疗增敏剂的成功表明，它还可能增强免疫检查点抑制剂的疗效并扩大其获益。
